Wegovy weight loss injections before and after: what the clinical evidence shows

Step 1: the early weeks — adjustment, not transformation

The first pen of Wegovy is dosed at 0.25mg. A prescriber starts here for a straightforward reason: it gives your digestive system time to settle. Nausea, loose stools and a queasy feeling after eating are the most commonly reported side effects, and they tend to be most noticeable in the first fortnight after each dose step. Pushing to a higher dose too quickly makes those effects worse, not faster. So the first four to eight weeks are not where dramatic change happens. Appetite may begin to dip, portions may feel larger than they used to, but the weight on the scale often moves slowly.

That early period matters for another reason. Building the habit of the weekly injection, understanding how to store the pen (refrigerated, between 2 and 8°C), rotating injection sites between abdomen, thigh and upper arm, and keeping a rough log of how you feel all sets you up better for the months ahead. If you want a thorough grounding in what the medicine involves before you begin, our guide to Wegovy weight loss injections covers storage and injection technique in more detail.

One practical note from our prescribers: patients who start in January or just before a bank holiday sometimes worry about interruptions to their supply. Ordering before a long weekend, rather than on the day you run out, avoids that pressure entirely.

Step 2: the middle months, when the before-and-after difference becomes visible

As the dose steps up through 0.5mg, then 1.0mg, then 1.7mg across roughly four-week intervals, appetite suppression deepens. Gastric emptying slows. Many people find they stop mid-meal because they feel full, sometimes for the first time in years. This is the period most often captured in before-and-after accounts of Wegovy injections: roughly weeks 12 through 36, when the body has had time to respond to a therapeutic dose and cumulative calorie reduction starts to show.

The STEP 1 trial, published in the New England Journal of Medicine, randomised 1,961 adults with obesity and showed that weight loss continued throughout the 68-week treatment period, with the steepest decline in the middle section of the trial. Participants who also made structured lifestyle changes lost more weight than those who did not. Wegovy is not a standalone intervention, the licence specifically includes reduced-calorie diet and increased physical activity alongside the medicine.

Side effects for most people ease as the body adapts, though they can return briefly at each dose step. Severe, persistent stomach pain that spreads to the back needs urgent medical attention; the MHRA's Drug Safety Update guidance on GLP-1 medicines highlights acute pancreatitis as a known, if infrequent, serious risk. Any new or worsening symptoms should be discussed with a prescriber or your GP promptly.

Step 3: the maintenance phase, plateau, consolidation, and the 5% checkpoint

Most people reach the 2.4mg maintenance dose by around week 16 to 20. Weight loss does not stop there, but it does slow. The body defends against a large calorie deficit by adapting metabolic rate and hunger signals over time, which is why the pace of change visible in before-and-after comparisons typically levels off toward the end of treatment. That is not failure; it is physiology.

NICE guidance on semaglutide (TA875) recommends that if a person has not lost at least 5% of their starting body weight after six months at the maintenance dose, continuing the medicine should be reviewed. That threshold is a clinical benchmark, not a target to aim for in the first weeks. If you are exploring what Wegovy treatment looks like week by week, the Wegovy information page sets out the full licensed dose schedule.

For people considering the cost side of treatment alongside clinical questions, the weight loss treatments overview explains what private treatment typically includes and what to look for in a provider.

What shapes the range of results, and why individual outcomes vary

Before-and-after photographs and forum threads capture real people, but they are not representative samples. The STEP 1 trial average of around 15% masks a genuine spread: some participants lost far more, some considerably less. Factors that influence where someone lands include starting weight, how closely they maintained diet and activity changes, whether side effects interrupted titration, and individual biological response to GLP-1 receptor agonism. If you want to understand how the Wegovy weight loss pen fits into the full treatment journey, including how the device itself works and what to expect at each dose stage, that detail can help set realistic expectations alongside the clinical picture. Semaglutide acts on a single receptor pathway; its mechanism is well understood, but human metabolic variation is wide.

The NHS semaglutide medicine page gives a clear summary of what the medicine does, how it works and what to watch for. If you are comparing semaglutide with tirzepatide, which activates two receptor pathways and showed greater average weight loss in the SURMOUNT-5 head-to-head trial, our semaglutide page walks through the differences between them. Which medicine suits you is a clinical decision, not a marketing one, and our prescribers are the right people to work through it with.

Wegovy is not licensed for under-18s, and it is not recommended during pregnancy, breastfeeding, or while trying to conceive. A prescriber reviews every application individually; eligibility is never assumed from BMI alone.

If you are ready to find out whether Wegovy could be appropriate for you, start your free consultation with our clinical team. A GPhC-registered prescriber reads every application the same day.